C4 Therapeutics, Inc. (CCCC) News
Follow C4 Therapeutics, Inc. (CCCC) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 10 public stories across 5 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
C4 Therapeutics Reports Quarterly Results Through September 30
EQUITY | Nov 05, 2026, 08:17 PM UTC
M
C4 Therapeutics Reports Third-Quarter Revenue of $8.5M
EQUITY | Nov 05, 2026, 12:31 PM UTC
M
C4 Therapeutics Reports Third-Quarter 2026 Results and Trial Update
The company said enrollment in its Phase 2 MOMENTUM trial of cemsidomide remains on track to finish in the first quarter of 2027, with initial ORR data expected.
EQUITY | Nov 05, 2026, 12:03 PM UTC
M
C4 Therapeutics Q3'26 EPS Estimate Is $(0.20)
The company is scheduled to report Q3'26 results on October 29; the release time is not specified in the headline, while the body also cites 8:00 a.m. ET (12:00 p.m. UTC).
EQUITY | Oct 28, 2026, 11:04 AM UTC
L
C4 Therapeutics presents Phase 1 biomarker gains for cemsidomide; 75 µg combo dose with elranatamab declared safe
C4 Therapeutics reported new biomarker data showing T—cell activation from the cemsidomide Phase 1 trial and supportive preliminary Phase 1b data with elranatamab; the 75 µg combination dose was declared safe and the Pha
NEWS | Sep 25, 2026, 11:14 AM UTC
L
C4 Therapeutics, Inc. (CCCC) Reports Early Biomarker and Safety Updates in Cemsidomide Combos
C4 Therapeutics presented biomarker data showing T—cell activation with cemsidomide and said the 75 µg dose with elranatamab was declared safe, enabling expansion at 75 µg and escalation to 100 µg; full Phase 1b cohort d
NEWS | Sep 25, 2026, 11:01 AM UTC
L
C4 Therapeutics Presents New Biomarker Data from the Cemsidomide Phase 1 Trial with Dexamethasone and Phase 1b Trial with Elranatamab (ELREXFIO®) in Relapsed/Refractory Multiple Myeloma at the 23rd International Myeloma Society (IMS) Annual Meeting
Immunomodulatory Effects of Cemsidomide with Dexamethasone from Phase 1 Trial Demonstrated Robust T-cell Activation, a Key Component of Cemsidomide’s Dual Mechanism of ActionBiomarker Data from First Two Patients in Phas
NEWS | Sep 25, 2026, 11:01 AM UTC
L
C4 Therapeutics to present new biomarker data for cemsidomide plus dexamethasone
C4 Therapeutics said it will present new biomarker data on the immunomodulatory effects of cemsidomide in combination with dexamethasone from its Phase 1 relapsed/refractory multiple myeloma trial at the 23rd IMS Annual
EQUITY | Sep 03, 2026, 11:08 AM UTC
L
C4 Therapeutics to present biomarker data on cemsidomide plus dexamethasone
C4 Therapeutics said it will present new biomarker data on cemsidomide’s immunomodulatory effects with dexamethasone from its Phase 1 relapsed/refractory multiple myeloma trial at IMS.
EQUITY | Sep 03, 2026, 11:00 AM UTC
L
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Creative Medical Tech (NASDAQ: CELZ ) stock moved upwards by 242.5% to $2.77 during Tuesday's regular session. The market value of their outstanding shares is at $2.9 million. Cuprina Holdings (Cayman) (NASDAQ: C
EQUITY | Jun 30, 2026, 05:05 PM UTC